Oral and Oropharyngeal Squamous Cell Carcinoma
Oral and oropharyngeal squamous cell carcinoma (OSCC/OPSCC) is a malignancy arising from neoplastic change in the stratified squamous epithelium lining the mouth (tongue, floor of mouth, buccal mucosa, gums) and the oropharynx (tonsils, soft palate, base of tongue, posterior pharyngeal wall). The causes of this cancer have shifted markedly in recent decades: from the traditional risk factors of accumulated toxic exposure (tobacco, alcohol, betel quid chewing) to a sharp rise in oropharyngeal cancers caused by high-risk human papillomavirus (HPV), with HPV 16 responsible for more than 85–90% of virus-related OPSCC cases.
These different causes produce two clinical forms with opposite biology. HPV-related cancer tends to affect younger people with no history of smoking or drinking, yet responds better to treatment and carries a significantly better survival outlook. Tobacco- and alcohol-related cancer, by contrast, carries direct p53 gene mutations and a higher risk of spread and recurrence.
At Haute-Derma, oral and oropharyngeal cancer screening is a complete pathway: narrow band imaging endoscopy (NBI/mucoscopy), immunohistochemistry for the p16INK4a biomarker and molecular HPV RNA/DNA testing. We then work with oncology centers on superpulsed CO2 laser microsurgery that preserves speech and swallowing, followed by long-term surveillance for recurrence.
Pathogenesis: HPV-Driven vs. Tobacco- and Alcohol-Driven Pathways
HPV16 Genome Integration Pathway (HPV+ OPSCC)
- E6/E7 mechanism: HPV16 DNA integrates into the genome of oropharyngeal epithelial cells and overproduces two oncoproteins, E6 and E7. E6 promotes proteasomal degradation of p53, while E7 binds and inactivates pRb, pushing the cell into continuous S phase.
- p16INK4a overexpression: Loss of pRb removes a negative feedback loop, so p16INK4a protein builds up diffusely throughout the tumor cells. Strong, diffuse p16 staining (block positivity) is recognized by the WHO as the most reliable surrogate marker for HPV-related OPSCC.
Tobacco/Alcohol Mutation Pathway (HPV– OSCC/OPSCC)
- Direct accumulation of mutations: Chemical carcinogens (polycyclic aromatic hydrocarbons in tobacco, acetaldehyde from alcohol) damage DNA directly, causing loss-of-function mutations in TP53 and inactivation of CDKN2A (the gene encoding p16).
- Characteristics: These patients are p16-negative, have widespread field cancerization across the mucosa, and face a very high risk of a second primary cancer.
Clinical Features and Differences Between OSCC and OPSCC
Oral Squamous Cell Carcinoma (OSCC, Usually HPV–):
- Clinical features: An ulcer that has not healed for more than 2 weeks, with a hard raised edge and a fungating or necrotic base that bleeds easily on touch; or a white patch (leukoplakia) or red patch (erythroplakia) that cannot be scraped off.
- Sites: Lateral border of the tongue, floor of the mouth, buccal mucosa and the lower alveolar ridge.
Oropharyngeal Squamous Cell Carcinoma (OPSCC, Usually HPV+):
- Hidden primary tumor: The primary tumor in the tonsil or base of tongue is often tiny and sits deep in the tonsillar crypts, making it hard to see on routine examination.
- Cystic neck node metastasis: More than 50% of patients with HPV+ OPSCC first present with a painless, soft, cystic lump in the neck (levels I/II), which is easily mistaken for a branchial cleft cyst or neck abscess.
- Symptoms: Persistent one-sided sore throat, a sensation of something stuck when swallowing, pain radiating to the ear on the same side (referred otalgia) and voice changes.
Differential Diagnosis of Oral and Oropharyngeal Mucosal Lesions
| Feature | HPV(+) OPSCC* | Tobacco/Alcohol-Related (HPV–) OSCC* |
|---|---|---|
| Nature | HPV-related malignancy | Toxin-related malignancy |
| Age / History | Young to middle-aged (30–50 years), non-smokers | Older (50–70 years), heavy smoking/drinking |
| Lesion appearance | Prominent cystic neck node, hidden tonsillar tumor | Hard-edged ulcer, red/white patches |
| p16INK4a staining | Strong, diffuse positivity (>70%) | Usually negative |
| 5-year survival | Very high (80–90%) | Lower (40–50%) |
Diagnostic Process at Haute-Derma
Narrow Band Imaging (NBI) Endoscopy and Microscopic Mucoscopy:
- NBI technology: Uses 415 nm and 540 nm light, which hemoglobin absorbs strongly, to highlight the abnormal, tortuous intrapapillary capillary loops (IPCL) of early-stage cancer.
Biopsy and Immunohistochemistry (IHC):
- Punch biopsy or endoscopic biopsy: Looks for keratinocyte atypia, abnormal mitoses, keratin pearls and invasion through the basement membrane.
- p16INK4a staining: The gold standard for classifying OPSCC as HPV(+) or HPV(–).
Fine-Needle Aspiration (FNA) of Neck Nodes and ISH Testing:
- Ultrasound-guided FNA of suspicious neck nodes.
- In situ hybridization (ISH) or real-time RT-PCR for E6/E7 mRNA to confirm active HPV infection.
Treatment and Screening Strategy at Haute-Derma
Modern Microsurgery at Haute-Derma in Partnership with Oncology
- Transoral CO2 Laser Microsurgery (TLM): Used for early-stage (T1, T2) OSCC/OPSCC. The superpulsed CO2 laser vaporizes and removes the tumor precisely with safe microscopic margins, minimizing damage to the throat structures and avoiding the need to split the jaw or perform a tracheostomy.
- Treatment de-escalation for HPV(+) OPSCC: Because HPV(+) tumor cells are very sensitive to radiation and chemotherapy, these patients may receive reduced-dose regimens that limit long-term side effects (dry mouth, neck fibrosis, swallowing difficulty) while maintaining high survival rates.
Regular Screening and Vaccination
- Regular NBI screening: We recommend that high-risk individuals (genital HPV infection, oral sex, smoking) have an oral mucoscopy/NBI check every 6 months at Haute-Derma.
- Gardasil 9 vaccination: Vaccinating both males and females with Gardasil 9 builds immunity that helps prevent HPV 16/18 infection of the oropharyngeal mucosa.
